ClinicalTrials.gg
RecruitingNCT03718936Updated May 9, 2025

ADNP Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing ADNP-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

An observational study in ADNP, Helsmoortel-Van Der Aa Syndrome and Autism Spectrum Disorder, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-05-09.

Sponsored by Icahn School of Medicine at Mount Sinai · Observational

How we know

From the registry’s dates

  • Started Nov 2017; still recruiting 9 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
30
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 773 studies in Autism Spectrum Disorder with a site in United States — 163 open to participants now, 203 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Planned enrollment
91st of 114
30 · median 132
Started
2017
with 38 others
Observational
114 of 773
23 open now
Primary completion
2027-03
later than 81 of 201 live
Registered
336th of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 91st largest by planned enrollment of the 114 observational ones that give a count, is one of 39 that started in 2017, is one of 114 observational ones, reaches primary completion later than 81 of the 201 other live ones, and was the 336th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

163 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 2 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

ADNP, also known as Activity Dependent Neuroprotective Protein, is a rare neurodevelopmental disorder caused by mutations encompassing the ADNP gene on chromosome 20. Clinically, ADNP syndrome is characterized by intellectual disability and global developmental delay. This study seeks to characterize ADNP-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.

Read the detailed description

Subjects with a variant in the ADNP gene will be asked to complete a battery of developmental, behavioral and medical assessments to better characterize gene-related neurodevelopmental deficits. This series of assessments takes place over the course of a three-day period. It includes the Autism Diagnostic Observation Schedule (ADOS), parent interviews regarding developmental history and behavior, a psychiatric evaluation, a neurology assessment, as well as a clinical genetic evaluation that includes a physical and vitals exam. Affected individuals, as well as biologically related siblings, will also undergo a series of sensory assessments, including a research EEG, visual evoked potential, and an eyetracking assessment. Family members present for the visit will also be asked to provide a blood and/or saliva sample for research genetics.

03

Conditions studied

  • ADNP
  • Helsmoortel-Van Der Aa Syndrome
  • Autism Spectrum Disorder

Keywords

  • ADNP
  • Intellectual Disability
  • Autism Spectrum Disorder
  • Global Developmental Delay
  • Neurodevelopmental Deficits
  • Developmental Disability
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Individuals for this cohort study will be selected from any population, provided that they have a variant in the ADNP gene and meet eligibility requirements.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible participants must have a documented variant affecting the ADNP gene that the research team determines to be likely or definitely pathogenic.
  • Eligible participants must be at least 2 years of age.

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Autism Diagnostic Observation Schedule (ADOS)

    The ADOS is a structured, play-based assessment of communication, social interaction and behavior in individuals (children and adults) suspected of having a diagnosis of Autism Spectrum Disorder. The examiner will select 1 of 4 different ADOS modules, which differ based on chronological age and verbal fluency, to use for the individual being assessed. An Overall Total score \>= 16, if the individual meets for the "few to no words" algorithm, or 12, if the individual meets for the "some words" algorithm, suggests autism in the individual. An Overall Total score of 11 to 15, if the individual meets for the "few to no words" algorithm, or 8 to 11, if the individual meets for the "some words" algorithm, suggests the individual is on the autism spectrum. An Overall Total score equal to or lower than 10, if the individual meets for "few to no words" algorithm, or 7, if the individual meets for the "some words" algorithm, classifies the individual as "non-spectrum" or not on the spectrum.

    Time frame: Day 1

Secondary outcomes

  1. Autism Diagnostic Interview - Revised (ADI-R)

    The ADI-R is a standardized, semi-structured clinical assessment used to diagnose Autism Spectrum Disorder (ASD) in children and adults. The ADI-R is a structured interview administered by an examiner to the primary caregiver of children and adults suspected of having ASD. The assessment contains 93 items, scored from 0 (behavior not present) to 279 (severe or frequent behavior). A higher assessment score indicates poorer outcomes.

    Time frame: Day 1

  2. Stanford-Binet Intelligence Scales

    The Stanford-Binet Intelligence Scales are a cognitive assessment measuring the five factors of fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing and working memory. The number of correct responses for the subtests is converted to a Standard Age Score, based on the chronological age of the individual being assessed. The Area Scores and Test Composite on the Stanford-Binet test have an average score of 100 and a standard deviation of 16. The converted score of the individual being assessed indicates where he/she is relative to the norm. A score exceeding 145 is classified as "Genius or near genius," and scores below 70 are classified as "Borderline deficiency."

    Time frame: Day 1

  3. Differential Ability Scales (DAS)

    The DAS is a battery of cognitive and achievement testing for children 2.5-18 years old that is divided into Early Years and School-Age versions. The 20 subtests of the DAS are broken up into 17 cognitive and 3 achievement subtests. The scores of the test are categorized into i) General Conceptual Ability (GCA) which is based on the ability of the individual being assessed to perform complex mental processing involving transformation of information ii) cluster scores that indicate verbal, spatial and nonverbal reasoning abilities and iii) subtest scores that represent specific abilities or processes. The tests yield t-scores and percentiles by age.

    Time frame: Day 1

  4. Mullen Scales of Early Learning

    The Mullen Scales of Early Learning are a clinical assessment used to measure cognitive ability and motor development in children ages 0-68 months on the five scales of Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. T-scores, percentile rankings, and age equivalents can be calculated for each of these five scales.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2017 (actual). Primary completion is estimated for Mar 2027, 112 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2018
First posted
Oct 25, 2018
StartActual
Nov 14, 2017
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
May 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03718936
Collaborators
The Seaver Foundation, Autism Science Foundation, Research Foundation for Mental Hygiene, Inc.
Responsible party
Alexander Kolevzon (Clinical Director of the Seaver Autism Center for Research and Treatment, Professor of Psychiatry and Pediatrics and Director of Child and Adolescent Psychiatry, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Oct 25, 2018
Start date
Nov 14, 2017
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
May 9, 2025

Study contacts

Tess Levy
Contact
tess.levy@mssm.edu
212-241-5290
Silvia De Rubeis, Ph.D.
principal investigator · Icahn School of Medicine at Mount Sinai
Paige Siper, Ph.D.
principal investigator · Icahn School of Medicine at Mount Sinai
Alexander Kolevzon, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion